3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
7
Withdrawn
2
Not yet recruiting
2
Active not recruiting
2
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Squamous-Cell Non-Small-Cell Lung Cancer
1
Interventions
Cyclophosphamide
389
Carboplatin
343
Gemcitabine
331
pembrolizumab
328
Cisplatin
327
Paclitaxel
294
Radiotherapy
291
Docetaxel
285
Bevacizumab
249
Rituximab
233
Capecitabine
221
Nivolumab
218
Dexamethasone
205
Fluorouracil
189
fludarabine
177
Oxaliplatin
177
Pemetrexed
153
Doxorubicin
152
Irinotecan
147
Etoposide
144
Leucovorin
143
Cytarabine
133
Bortezomib
129
fludarabine phosphate
128
Cetuximab
126
Lenalidomide
125
Filgrastim
119
Erlotinib Hydrochloride
119
Temozolomide
111
Radiosurgery
110
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Interventional
×
bemarituzumab
×
Clear all
NCT05267470
2025-03-25
FORTITUDE-201
Amgen
Phase 1
Terminated
74 enrolled
22 charts